Eli Lilly is paying up to $2.75 billion to partner with the AI drug discovery company founded by a man who takes Lilly's own weight-loss drug every day.
Alex Zhavoronkov, founder and chief executive of Insilico Medicine, disclosed in March 2026 that he personally uses Lilly's tirzepatide — sold as Mounjaro for diabetes and Zepbound for obesity — and called it "the best drug ever invented by humans." He wants to build the next one. Now Lilly is paying Insilico up to $2.75 billion to help him try, according to a press release published via PR Newswire. The deal includes $115 million upfront, with milestones and royalties bringing the total value to approximately $2.75 billion.
The Financial Times, citing unnamed sources, reported that Lilly is acquiring exclusive rights to a GLP-1 diabetes drug candidate from Insilico's pipeline. Insilico's own pipeline page was recently updated to note a GLP-1-targeting candidate has been out-licensed to an undisclosed partner, STAT News observed. That detail — not the headline dollar figure — is the actual story.
The deal is the culmination of a relationship that began in secret. The two companies first collaborated in 2023 via an AI-based software licensing agreement that was never publicly disclosed at the time, FierceBiotech reported. They went public with a $100 million-plus expanded partnership in November 2025. The March 2026 announcement escalates that into full co-development of novel oral therapeutics, with Lilly holding exclusive worldwide rights to develop, manufacture, and commercialize the results.
What changed between November and March isInsilico's financial position. The company posted a 2025 net loss of $352.3 million on just $56.24 million in revenue — a steep deterioration from a $17.1 million loss in 2024. Cash on hand stood at $393.3 million as of December 31, 2025. The deal announcement landed on the same evening Insilico released those results. Andrew Adams, Lilly's group vice president of molecule discovery, said in a statement that Lilly was looking for partners that could move at its pace — a not-so-subtle signal about what big pharma is demanding from AI-native biotechs right now.
Zhavoronkov, for his part, has been unusually candid about what Lilly brings to the table. "In many ways, Lilly is better than us in some areas of AI," he told CNBC, pointing specifically to a single person at Lilly who "brought biology, chemistry and automation under one roof." That kind of admission from a biotech CEO about a partner is rare. It suggests this is less a partnership between equals and more a transaction between a company with validated manufacturing reach and a company with an AI engine that still needs to prove its molecules can make it to market.
Insilico has 10 programs currently in clinical trials and has nominated 28 preclinical candidates total, according to its 2025 annual results. Its Pharma.AI software platform — consisting of Biology42, Chemistry42, and Medicine42 — already serves 13 of the top 20 global pharmaceutical companies, the company said. The Rentosertib program for idiopathic pulmonary fibrosis produced Phase IIa results published in Nature Medicine on June 3, 2025, which Insilico called the first proof-of-concept clinical validation of an AI-discovered drug.
Lilly is not the only large pharma working with Insilico. The company has collaboration agreements with Servier worth up to $888 million in oncology and with Qilu Pharmaceutical worth up to $120 million in cardiometabolic disease, FierceBiotech noted. But the Lilly deal is by far the largest and the most strategically sensitive — particularly given the GLP-1 angle.
Zhavoronkov has not ruled out an eventual acquisition. "We can't comment on M&A speculation, but are committed to our current collaborations," he said, according to GEN News. The deal structure — Lilly getting exclusive global rights — suggests Lilly is building toward something it wants to own outright. Whether that something is a single GLP-1 candidate or the whole AI discovery engine is the question the next twelve months should answer.
As part of the agreement, Insilico will join Lilly's Gateway Labs community for biotech development — a network the company has been building to anchor early-stage companies near its research operations. That kind of structural integration is how acquisitions start.
The broader context is a pharmaceutical industry that is rapidly consolidating around AI drug discovery capabilities. Lilly separately announced a co-innovation lab with Nvidia, committing up to $1 billion over five years to build AI infrastructure for drug discovery. CEO David Ricks attended a high-level forum in Beijing in March 2026, weeks after Lilly announced a $3 billion investment in China over the next decade — a signal that the company is threading a careful geopolitical needle in a market where both Lilly and Insilico have significant operations.
For Zhavoronkov, who founded Insilico in 2014 with the stated goal of replacing animal testing in drug discovery, the deal marks a moment of arrival. He has spent more than a decade arguing that AI could compress the time and cost of drug development. Now one of the world's largest pharmaceutical companies is paying him billions to prove it — while he himself uses the company's drug every day and says he wants to make something better. What he hands Lilly over that period will be the first real test of whether Insilico's AI engine can deliver molecules at commercial scale, not just in journal pages.
What to watch next: whether the GLP-1 candidate Insilico has out-licensed to Lilly enters IND-enabling studies this year, and whether Insilico's cash position forces it to seek additional partnerships or whether the Lilly deal gives it sufficient runway to build toward profitability without diluting further.
